We use necessary cookies to make our website work. We'd also like to use optional cookies to understand how you use it, and to help us improve it.

For more information, please read our cookie policy.



General advice for flying / controlling post vaccination or immunisation

  • In the absence of any side-effects 12 hours after vaccination there are no restrictions to resuming flying or controlling duties.
  • Should a pilot or ATCO develop a fever or feel unwell, whether associated with vaccination or not, they should not fly or control until symptoms have resolved and/or they have been cleared to fly by their AME/physician.

The following are the requirements for the medical certification of aircrew, including guidance material issued by the UK CAA Medical Department in relation to Infectious diseases.

MED.B.040 Infectious Disease

Implementing Rules

  1. Applicants shall be assessed as unfit where they have a clinical diagnosis or medical history of any infectious disease which is likely to jeopardise the safe exercise of the privileges of the licence.
  2. Applicants who are HIV positive may be assessed as fit subject to satisfactory aero-medical evaluation. Such applicants for a class 1 medical certificate shall be referred to the medical assessor of the licensing authority.
Close Implementing Rules

Acceptable Means of Compliance

CLASS 1 - AMC1 MED.B.040

(a) Infectious disease General

In cases of infectious disease, consideration should be given to a history of, or clinical signs indicating, underlying impairment of the immune system.

(b) Tuberculosis

(1) Applicants with active tuberculosis should be assessed as unfit. A fit assessment may be considered following completion of therapy.

(2) Applicants with quiescent or healed lesions may be assessed as fit. Specialist evaluation should consider the extent of the disease, the treatment required and possible side effects of medication.

(c) Syphilis
Applicants with acute syphilis should be assessed as unfit. A fit assessment may be considered in the case of those fully treated and recovered from the primary and secondary stages.

(e) Infectious hepatitis
Applicants with infectious hepatitis should be assessed as unfit. A fit assessment may be considered once the applicant has become asymptomatic. Regular review of the liver function should be carried out.

CLASS 2 - AMC2 MED.B.040

Infectious disease

(a) Tuberculosis

(1) Applicants with active tuberculosis should be assessed as unfit. A fit assessment may be considered following completion of therapy.

(2) Applicants with quiescent or healed lesions may be assessed as fit. Specialist evaluation should consider the extent of the disease, the treatment required and possible side effects of medication.

UK Alternative AMC1 to MED B.040 (d) HIV positivity

(d) HIV positivity

(1) Applicants who are HIV positive may be assessed as fit if a full investigation provides no evidence of HIV associated diseases that might give rise to incapacitating symptoms. Frequent review of the immunological status and neurological evaluation by an appropriate specialist should be carried out. A cardiological evaluation may also be required, depending on the medication. An OML should be applied as appropriate.

(2) Applicants with signs or symptoms of an AIDS defining condition should be assessed as unfit.

CLASS 2 - AMC2 MED.B.040

(b) HIV positivity

(1) Applicants who are HIV positive may be assessed as fit if a full investigation provides no evidence of HIV associated diseases that might give rise to incapacitating symptoms. Frequent review of the immunological status and neurological evaluation by an appropriate specialist should be carried out. A cardiological evaluation may be required, depending on the medication.

(2) Applicants with signs or symptoms of an AIDS-defining condition should be assessed as unfit.

Close Acceptable Means of Compliance

News from UK Civil Aviation Authority

  1. UK Civil Aviation Authority gives Santa permission to enter airspace
  2. Snow your rights before jetting off this Christmas
  3. UK regulator unveils new AI strategy